ArticleFrontiers in pharmacology2026
Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations: a cost-utility analysis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The FABULOUS trial showed that fuzuloparib, with or without apatinib, significantly improved progression-free survival (PFS) in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer with germline breast cancer susceptibility genes 1 or 2 mutations compared to standard chemotherapy. The study assessed the cost-effectiveness of three treatment options from the perspective of China's healthcare system. Methods: A partitioned survival model was created to evaluate cost-effectiveness. The model incorporated direct medical costs, with drug prices derived from local charges and other costs as well as utility data from published literature. Both costs and utility values were discounted at an annual rate of 4.5%. The incremental cost-effectiveness ratio (ICER) served as the primary outcome. The treatment regimen was determined to be cost-effective if the ICER was below the willingness-to-pay (WTP) threshold of $26,083/quality-adjusted life year (QALY). One-way sensitivity, probabilistic sensitivity and scenario analyses were also conducted. Results: The ICERs for fuzuloparib versus chemotherapy, fuzuloparib versus fuzuloparib-apatinib, and fuzuloparib-apatinib versus chemotherapy were calculated as $141,912.74/QALY, $285,196.26/QALY, and $90,074.03/QALY, respectively. Accordingly, neither fuzuloparib plus apatinib nor fuzuloparib monotherapy was found to be cost-effective compared with standard chemotherapy at the WTP threshold of $26,083/QALY. Moreover, fuzuloparib monotherapy was not cost-effective compared with fuzuloparib plus apatinib. Sensitivity and scenario analyses affirmed the robustness of the model. One-way sensitivity analysis showed that utility for PFS, utility for progressive disease, and costs associated with subsequent treatment exerted the most substantial influence on the outcomes. Conclusion: Although fuzuloparib, with or without apatinib, has shown substantial clinical benefits, it has not proven to be cost-effective when compared to standard chemotherapy. Further global multicenter or population-specific clinical trials involving breast cancer patients are necessary to enhance the understanding of the application scope and cost-effectiveness of fuzuloparib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.